Abstract:Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation (alloHSCT), this effect has been largely mitigated in older and less fit patients as well as those with adverse-risk disease characteristics. However, the last 10 years has been marked by major advances in the molecular profiling of AML characterized by a deeper understanding of disease pathobiology and therapeutic vulnerabilities. In this regard, the classification of AML subtypes has recently evolved from a morphologic to a molecular and genetic basis, reflected by recent updates from the World Health Organization and the new International Consensus Classification system. After years of stagnation in new drug approvals for AML, there has been a rapid expansion of the armamentarium against this disease since 2017. Low-intensity induction therapy with hypomethylating agents and venetoclax has substantially improved outcomes, including in those previously considered to have a poor prognosis. Furthermore, targeted oral therapies against driver mutations in AML have been added to the repertoire. But with an accelerated increase in treatment options, several questions arise such as how to best sequence therapy, how to combine therapies, and if there is a role for maintenance therapy in those who achieve remission and cannot undergo alloHSCT. Moreover, certain subtypes of AML, such as those with TP53 mutations, still have dismal outcomes despite these recent advances, underscoring an ongoing unmet need and opportunity for translational advances. In this review, we will discuss recent updates in the classification and risk stratification of AML, explore the literature regarding low-intensity and novel oral combination therapies, and briefly highlight investigative agents currently in early clinical development for high-risk disease subtypes.

Challenges and emerging therapeutic strategies for TP53-mutated acute myeloid leukemia: still disappointing findings?

Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

Recent advances in targeted therapies in acute myeloid leukemia

What have we learned about TP53- mutated acute myeloid leukemia?

FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

p53 biology and reactivation for improved therapy in MDS and AML

Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53 -mutant myelodysplastic neoplasms and acute myeloid leukemia

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

The Landscape of Novel Strategies for Acute Myeloid Leukemia Treatment: Therapeutic Trends, Challenges, and Future Directions

TP53 in MDS and AML: Biological and Clinical Advances.

Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia

Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities